Cynata Therapeutics (ASX:CYP) formerly known as EcoQuest (ASX:ECQ) has taken the leap into stem cells as a result of an acquisition of Cynata Inc which is developing a stem cell therapeutic technology.
Cynata has focused its attention on the Cymerus technology as it is called, which seeks to fill a gap in the process of taking stem cells from the laboratory into widespread therapeutic use.
Potentially it could enable the manufacture of billions of human stem cells to facilitate commercial-scale production.
The technology originated from the renowned University of Wisconsin-Madison, a world leader in stem cell research. Cynata has a License Agreement with Wisconsin Alumni Research Foundation.
The proprietary Cymerus™ technology seeks to address a shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale.
Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA).
The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale.
This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
Cynata Inc’s co-founder, Professor Igor Slukvin, will be a keynote speaker at the NSW Stem Cell Network Conference to be held in Sydney on November 29.
Professor Slukvin, from the University of Wisconsin – Madison, has an outstanding international reputation having published more than 70 scientific papers and being an inventor on a range of patents in the fields of regenerative medicine and human pluripotent stem cell biology.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.